VICTORION-INCEPTION: Inclisiran Immediately After ACS for Secondary Prevention
VICTORION-INCEPTION is a phase IIIb, randomized, parallel-group, open-label, multicenter, US-based...
Read MoreNov 15, 2022
VICTORION-INCEPTION is a phase IIIb, randomized, parallel-group, open-label, multicenter, US-based...
Read MoreNov 15, 2022
The principal finding from a 4-year open-label extension study of inclisiran—a small interfering...
Read MoreNov 15, 2022
For patients with refractory/relapsed acute myeloid leukemia (AML), total therapy, as compared...
Read MoreNov 14, 2022
Compared with their White counterparts, gout is more prevalent in Black adults, according to the...
Read MoreNov 14, 2022
Compared with patients with gout who did not experience a cardiovascular (CV) event, those who did...
Read MoreNov 8, 2022
In a randomized-controlled trial, cognitive rehabilitation therapy (CRT) and mindfulness-based...
Read MoreNov 8, 2022
Discontinuing natalizumab during the first trimester of pregnancy increased relapse risk during...
Read MoreNov 8, 2022
Do disease-modifying therapies (DMTs) in everyday practice delay the progression of disease in...
Read MoreNov 8, 2022
New research suggests that not only is MS preceded by Epstein-Barr virus (EBV) infection, but it...
Read MoreNov 8, 2022
Immune ablation with autologous hematopoietic stem cell transplantation (AHSCT) was not superior...
Read MoreNov 8, 2022
Disease progression independent of relapse activity (PIRA) was found to be less frequent in...
Read MoreNov 8, 2022
Treatment with ravulizumab was highly effective in reducing risk for relapse in patients with...
Read MoreNov 8, 2022
A large amount of preclinical and clinical research has been dedicated to remyelination in MS,...
Read MoreNov 8, 2022
A non-inferiority comparative study failed to demonstrate that treatment with rituximab is...
Read MoreNov 8, 2022
An analysis of patient-reported outcomes (PRO) over a 10-year period suggests that physical...
Read MoreNov 8, 2022
Non-disabling relapses (NDRs) that occur early in the course of relapsing-remitting MS (RRMS) are...
Read MoreNov 8, 2022
For the first time, a randomized, placebo-controlled trial demonstrated beneficial effects of a...
Read MoreNov 8, 2022
For a presentation at the 2022 European Committee for Treatment and Research in Multiple Sclerosis...
Read MoreNov 8, 2022
Data from a randomized controlled trial presented at the European Committee for Treatment and...
Read MoreNov 8, 2022
Nearly half of the TikTok videos on irritable bowel syndrome (IBS) are shared by social media...
Read More